Eureka Genomics to Merge with Nanobac Pharma | GenomeWeb

NEW YORK (GenomeWeb News) – Eureka Genomics plans to merge with Nanobac Pharmaceuticals under a stock and cash deal, the bioinformatics company said today.

Under a memorandum of understanding, Eureka stockholders will receive new shares of Nanobac common stock and own 85 percent of the combined company, which will operate under the Eureka Genomics name. Nanobac has already provided Eureka with initial funds, and the deal is expected to close in the second quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.